ReviewDiscover oncology2025
Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly(ADP-ribose) polymerases (PARPs) are important nuclear protein enzymes (NPEs) that play crucial functions in different cellular activities including DNA repair, gene transcription, post-translational, and cell death. Of the 17 established PARP family members, PARP-1 is a NPE with 113-116 kDa which is encoded by a gene found on chromosome 1q41-q42-1, and is the most abundant enzyme, with approximately 1-2 million molecules per cell, acting principally as a DNA damage sensor. PARP-1 has become an auspicious biological novel target for management of various cancers. Increased expression of PARP-1 has been documented in various types of malignancies such as melanomas, lung cancers, and breast cancers (BCs), and is associated with disease progression and reduced survival outcome. Expression of PARP-1 has been valuable as a prognostic factor in patients with BC especially triple negative phenotype and also human epidermal receptor-2 enriched compared to luminal subtypes. The prognostic role of PARP-1 in BCs is based on the use of PARP-1 inhibitors such as olaparib and talazoparib which usually inhibit the cancer cells from undergoing repair through homologous recombination repair (HRR) and base excision repair (BER), hence leading to their death. This review dissects the level of expression of PARP-1 and its association in different immunohistochemically determined molecular subtypes of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.